Analgesics
Antiandrogens
Antihistamines
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchVitamin CVitamin C (more..)
Metformin Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta Thermotherapy Meta
Melatonin Meta

All Studies   Meta Analysis       

The significance of oral ascorbic acid in patients with COVID-19

Patel et al., Chest Infections, doi:10.1016/j.chest.2020.08.322
Oct 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 29% Improvement Relative Risk Mortality (b) 16% Vitamin C for COVID-19  Patel et al.  LATE TREATMENT Is late treatment with vitamin C beneficial for COVID-19? Retrospective 176 patients in the USA Lower mortality with vitamin C (not stat. sig., p=0.18) c19early.org Patel et al., Chest Infections, October 2020 Favorsvitamin C Favorscontrol 0 0.5 1 1.5 2+
Vitamin C for COVID-19
6th treatment shown to reduce risk in September 2020, now with p = 0.00000004 from 74 studies, recognized in 12 countries.
Lower risk for mortality, ICU, hospitalization, and recovery.
No treatment is 100% effective. Protocols combine treatments.
5,300+ studies for 116 treatments. c19early.org
Retrospective 176 hospitalized patients, 96 treated with oral vitamin C (from 500mg to 1500mg daily), showing lower mortality with treatment.
This is the 4th of 74 COVID-19 controlled studies for vitamin C, which collectively show efficacy with p=0.00000004 (1 in 25 million).
21 studies are RCTs, which show efficacy with p=0.0012.
Standard of Care (SOC): SOC for COVID-19 in the study country, the USA, is very poor with very low average efficacy for approved treatments1. Only expensive, high-profit treatments were approved. Low-cost treatments were excluded, reducing the probability of treatment—especially early—due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments. This may explain in part the very high mortality seen in this study. Results may differ in countries with improved SOC.
risk of death, 29.5% lower, RR 0.71, p = 0.18, treatment 22 of 96 (22.9%), control 26 of 80 (32.5%), NNT 10.
risk of death, 15.6% lower, RR 0.84, p = 0.60, treatment 15 of 30 (50.0%), control 16 of 27 (59.3%), NNT 11, ICU patients.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Patel et al., 1 Oct 2020, retrospective, USA, peer-reviewed, 8 authors, dosage 1000mg days 1-4, 500mg to 1500mg daily.
This PaperVitamin CAll
THE SIGNIFICANCE OF ORAL ASCORBIC ACID IN PATIENTS WITH COVID-19
Manishkumar Patel, Gloria Hong, Bernadette Schmidt, Laith Al-Janabi, Radha Kishan Adusumilli, Jurgena Tusha, Padmini Giri, Sarwan Kumar
Chest, doi:10.1016/j.chest.2020.08.322
Our observational study showed even when ascorbic acid is administered in oral form as an adjunct to COVID-19 therapy, it is associated with a mortality benefit and improved extubation rate. DISCLOSURES: No relevant relationships by Radha Kishan Adusumilli, source¼Web Response No relevant relationships by Laith Al-janabi, source¼Web Response No relevant relationships by Padmini Giri, source¼Web Response No relevant relationships by Gloria Hong, source¼Web Response No relevant relationships by Sarwan Kumar, source¼Web Response No relevant relationships by Manishkumar Patel, source¼Web Response No relevant relationships by Bernadette Schmidt, source¼Web Response No relevant relationships by Jurgena Tusha, source¼Web Response
DOI record: { "DOI": "10.1016/j.chest.2020.08.322", "ISSN": [ "0012-3692" ], "URL": "http://dx.doi.org/10.1016/j.chest.2020.08.322", "alternative-id": [ "S0012369220325083" ], "author": [ { "affiliation": [], "family": "Patel", "given": "Manishkumar", "sequence": "first" }, { "affiliation": [], "family": "Hong", "given": "Gloria", "sequence": "additional" }, { "affiliation": [], "family": "Schmidt", "given": "Bernadette", "sequence": "additional" }, { "affiliation": [], "family": "Al-janabi", "given": "Laith", "sequence": "additional" }, { "affiliation": [], "family": "Adusumilli", "given": "Radha Kishan", "sequence": "additional" }, { "affiliation": [], "family": "Tusha", "given": "Jurgena", "sequence": "additional" }, { "affiliation": [], "family": "Giri", "given": "Padmini", "sequence": "additional" }, { "affiliation": [], "family": "Kumar", "given": "Sarwan", "sequence": "additional" } ], "container-title": "Chest", "container-title-short": "Chest", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2020, 10, 12 ] ], "date-time": "2020-10-12T10:45:50Z", "timestamp": 1602499550000 }, "deposited": { "date-parts": [ [ 2020, 12, 2 ] ], "date-time": "2020-12-02T15:14:58Z", "timestamp": 1606922098000 }, "indexed": { "date-parts": [ [ 2024, 3, 19 ] ], "date-time": "2024-03-19T07:16:51Z", "timestamp": 1710832611348 }, "is-referenced-by-count": 5, "issue": "4", "issued": { "date-parts": [ [ 2020, 10 ] ] }, "journal-issue": { "issue": "4", "published-print": { "date-parts": [ [ 2020, 10 ] ] } }, "language": "en", "license": [ { "URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2020, 10, 1 ] ], "date-time": "2020-10-01T00:00:00Z", "timestamp": 1601510400000 } } ], "link": [ { "URL": "https://api.elsevier.com/content/article/PII:S0012369220325083?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://api.elsevier.com/content/article/PII:S0012369220325083?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining" } ], "member": "78", "original-title": [], "page": "A325", "prefix": "10.1016", "published": { "date-parts": [ [ 2020, 10 ] ] }, "published-print": { "date-parts": [ [ 2020, 10 ] ] }, "publisher": "Elsevier BV", "reference-count": 0, "references-count": 0, "relation": {}, "resource": { "primary": { "URL": "https://linkinghub.elsevier.com/retrieve/pii/S0012369220325083" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Cardiology and Cardiovascular Medicine", "Critical Care and Intensive Care Medicine", "Pulmonary and Respiratory Medicine" ], "subtitle": [], "title": "THE SIGNIFICANCE OF ORAL ASCORBIC ACID IN PATIENTS WITH COVID-19", "type": "journal-article", "volume": "158" }
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit